INT55754

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.67
First Reported 1994
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 13
Total Number 13
Disease Relevance 16.43
Pain Relevance 0.24

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

Anatomy Mention Frequency
macrophages 1


Pain Term Frequency Confidence Heat
beta blocker 8 96.08 Very High Very High Very High
Inflammation 39 93.68 High High
corticosteroid 8 92.04 High High
alcohol 17 86.24 High High
Inflammatory response 8 54.64 Quite High
tolerance 1 54.08 Quite High
headache 18 25.00 Low Low
cva 57 15.56 Low Low
Bile 132 13.12 Low Low
Bioavailability 22 5.00 Very Low Very Low Very Low
Disease Term Frequency Confidence Heat
Disorder Of Lipid Metabolism 1314 99.90 Very High Very High Very High
Diabetes Mellitus 155 99.68 Very High Very High Very High
Hyperlipoproteinemia Type Ii 40 99.36 Very High Very High Very High
Pancreatitis 23 99.24 Very High Very High Very High
Hyperlipidemia 121 99.20 Very High Very High Very High
Hyperlipoproteinemia Type Iv 16 98.36 Very High Very High Very High
Disease 54 98.00 Very High Very High Very High
[[ /

[[]]]]

151 97.80 Very High Very High Very High
Hyperlipoproteinemia Type Iii 2 96.88 Very High Very High Very High
Familial Combined Hyperlipidemia 2 94.84 High High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Lastly, familial combined hyperlipoproteinemia is a Type IIb disorder that can cause elevated VLDL-C, LDL-C, or both.
Positive_regulation (cause) of VLDL-C associated with hyperlipoproteinemia type ii
1) Confidence 0.67 Published 2010 Journal Vascular Health and Risk Management Section Body Doc Link PMC2835557 Disease Relevance 0.89 Pain Relevance 0
Familiar HTG is an autosomal-dominant disorder with elevated levels of VLDL-cholesterol (VLDL-C) mainly due to large VLDL particles [12, 13••].
Positive_regulation (elevated) of VLDL-C associated with hyperlipidemia
2) Confidence 0.67 Published 2010 Journal Curr Diab Rep Section Body Doc Link PMC2890983 Disease Relevance 1.15 Pain Relevance 0
The lipid triad of the metS and T2DM consists of an elevation in VLDL-C or triglycerides, small dense atherogenic LDL-C, and a decrease in HDL-C.
Positive_regulation (elevation) of VLDL-C associated with diabetes mellitus and disorder of lipid metabolism
3) Confidence 0.67 Published 2005 Journal Cardiovasc Diabetol Section Body Doc Link PMC1079905 Disease Relevance 1.77 Pain Relevance 0.03
Lastly, familial combined hyperlipoproteinemia is a Type IIb disorder that can cause elevated VLDL-C, LDL-C, or both.
Positive_regulation (elevated) of VLDL-C associated with hyperlipoproteinemia type ii
4) Confidence 0.67 Published 2010 Journal Vascular Health and Risk Management Section Body Doc Link PMC2835557 Disease Relevance 0.83 Pain Relevance 0
High levels of LDL-C (and to a lesser extent, VLDL-C) result in the accumulation of LDL-C in the arterial wall, leading to oxidation of LDL-C.9 Oxidized LDL-C can cause extensive damage to the arterial wall, provoking inflammation responses, promoting coagulation, increasing the activity of mediators that cause vasoconstriction and inhibiting mediators that cause vasodilation.9 Oxidized LDL-C recruits monocytes, which enter the arterial wall and are activated to become macrophages.
Positive_regulation (result) of VLDL-C in macrophages associated with inflammation and increased venous pressure under development
5) Confidence 0.49 Published 2010 Journal Vascular Health and Risk Management Section Body Doc Link PMC2835557 Disease Relevance 1.77 Pain Relevance 0.21
Only after LDL-C levels are achieved does ATP III recommend treating other lipids, such as non–high-density lipoproteins (non-HDL-C), which consist of LDL-C and very low-density lipoproteins (VLDL-C), as a secondary target in patients with TG levels of 200 to 499 mg/dL.3 Drug therapy can only be used to increase HDL-C, also known as “good cholesterol,” in patients who have metabolic syndrome and a history of CHD or the risk equivalent.3 The current recommendations for treating LDL-C as the primary target are supported by most of the guidelines for cholesterol management.4–8
Positive_regulation (consist) of VLDL-C associated with coronary artery disease, metabolic syndrome and disorder of lipid metabolism
6) Confidence 0.49 Published 2010 Journal Vascular Health and Risk Management Section Body Doc Link PMC2835557 Disease Relevance 0.94 Pain Relevance 0
Gemfibrozil produced significantly greater changes in VLDL-C (p < 0.01), HDL-C (p < 0.001), and TG (p < 0.001), but not in LDL-C: HDL-C, compared with fluvastatin.
Positive_regulation (changes) of VLDL-C associated with disorder of lipid metabolism
7) Confidence 0.49 Published 1994 Journal Am. J. Med. Section Abstract Doc Link 8017467 Disease Relevance 1.23 Pain Relevance 0
Trilipix plus rosuvastatin 10 mg resulted in greater improvements in VLDL-C, apo B, and high-sensitivity C-reactive protein than rosuvastatin 10 mg.
Positive_regulation (improvements) of VLDL-C
8) Confidence 0.49 Published 2010 Journal Vascular Health and Risk Management Section Body Doc Link PMC2922314 Disease Relevance 0.24 Pain Relevance 0
The term hypertriglyceridemia usually refers to elevations in VLDL-C and chylomicrons, both of which carry and transport TG.5 Primary hypertriglyceridemia includes primary chylomicronemia, familial hypertriglyceridemia, familial combined hyperlipoproteinemia and familial dysbetalipoproteinsemia.12 Primary chylomicronemia is a genetic disease that is characterized by a deficiency in LPL or cofactor, and results in elevated chylomicrons and VLDL-C and severe elevation of TG, leading to acute pancreatitis.12 Familial hypertriglyceridemia is a Type IV disorder in which primarily VLDL-C is affected.9 It is caused by a number of genetic determinants that result in insufficient removal of TG-rich lipoproteins.12 Familial combined hyperlipoproteinemia is a disorder characterized by increased levels of VLDL-C, LDL-C, or both.
Positive_regulation (elevation) of VLDL-C associated with pancreatitis, hyperlipoproteinemia type ii, disease, hyperlipidemia, hyperlipoproteinemia type iv and disorder of lipid metabolism
9) Confidence 0.45 Published 2010 Journal Vascular Health and Risk Management Section Body Doc Link PMC2835557 Disease Relevance 1.71 Pain Relevance 0
The term hypertriglyceridemia usually refers to elevations in VLDL-C and chylomicrons, both of which carry and transport TG.5 Primary hypertriglyceridemia includes primary chylomicronemia, familial hypertriglyceridemia, familial combined hyperlipoproteinemia and familial dysbetalipoproteinsemia.12 Primary chylomicronemia is a genetic disease that is characterized by a deficiency in LPL or cofactor, and results in elevated chylomicrons and VLDL-C and severe elevation of TG, leading to acute pancreatitis.12 Familial hypertriglyceridemia is a Type IV disorder in which primarily VLDL-C is affected.9 It is caused by a number of genetic determinants that result in insufficient removal of TG-rich lipoproteins.12 Familial combined hyperlipoproteinemia is a disorder characterized by increased levels of VLDL-C, LDL-C, or both.
Positive_regulation (increased) of VLDL-C associated with pancreatitis, hyperlipoproteinemia type ii, disease, hyperlipidemia, hyperlipoproteinemia type iv and disorder of lipid metabolism
10) Confidence 0.45 Published 2010 Journal Vascular Health and Risk Management Section Body Doc Link PMC2835557 Disease Relevance 1.55 Pain Relevance 0
Familial dysbeta lipoproteinemia is a disorder characterized by increased levels of VLDL-C remnant and chylomicron remnant.9,12
Positive_regulation (increased) of VLDL-C
11) Confidence 0.45 Published 2010 Journal Vascular Health and Risk Management Section Body Doc Link PMC2835557 Disease Relevance 1.44 Pain Relevance 0
In addition very low density lipoprotein cholesterol (VLDL-C) (treated 0.4 +/- 0.3 vs controls 0.2 +/- 0.1 nmol/l, P < 0.05) was increased in T-treated patients.
Positive_regulation (increased) of VLDL-C
12) Confidence 0.45 Published 1998 Journal Clin. Endocrinol. (Oxf) Section Body Doc Link 9828903 Disease Relevance 0 Pain Relevance 0
There are six categories of lipoprotein disorders according to the Fredrickson-Levy-Lees classification: Type I (high levels of chylomicrons), Type IIa (high LDL-C levels), Type IIb (high LDL-C and VLDL-C levels), Type III (high IDL-C levels), Type IV (high VLDL-C levels), and Type V (high LDL-C and chylomicrons levels).9 It is also possible that some disease states can be placed into more than one category of lipoprotein disorder.
Positive_regulation (high) of VLDL-C associated with disease and disorder of lipid metabolism
13) Confidence 0.21 Published 2010 Journal Vascular Health and Risk Management Section Body Doc Link PMC2835557 Disease Relevance 1.94 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox